Recent Pfizer Press Releases

  • 11/18/14 8:30 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that TRUMENBA® (Meningococcal Group B Vaccine), the first and only FDA-approved vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age, is now available for order by healthcare providers in the United States. Serogroup B meningococcal meningitis is characterized by high fatality rates and rapid onset, oftenmore...
  • 11/17/14 2:53 am EST

    PD-L1 Antibody Clinical Results Consistent with Class; Interim Data Demonstrated A Complete and Partial Responses in Ovarian Cancer and NSCLC

    Up to 20 High Priority Immuno-Oncology Clinical Development Programs, Including Up to 6 Registration Trials, Expected to Commence in 2015

    Updates 2014 Reported Diluted EPS Range Solely to Reflect the Transaction

    Analyst Call Scheduled for 10 a.m. EST on Monday, November 17, 2014

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that it has entered into an agreement with Merck KGaA, Darmstadt, Germany, to jointly develop and commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck KGaA as a potential treatment for multiple types of cancer. Pfizer and Merck KGaA will explore the therapeutic potential of this novel anti-PD-L1 antibody as a single agent as well as in various combinations withmore...
  • 11/13/14 11:00 am EST

    Collaboration will help advance progress and support global efforts to increase access to voluntary family planning information, services and contraceptives by 2020

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc., the Bill & Melinda Gates Foundation and the Children’s Investment Fund Foundation (CIFF) today announced an agreement that will expand access to Pfizer’s injectable contraceptive, Sayana® Press (medroxyprogesterone acetate), for women most in need in 69 of the world’s poorest countriesi. Through this collaboration of organizations from the public and private sectors, Sayana® Press will be sold for US $1 per dose to qualifiedmore...
  • 11/12/14 8:00 am EST

    21 Abstracts, Including Additional Clinical Trial Data and Real-World Analyses, Add to the Body of Evidence for XELJANZ® (Tofacitinib Citrate) as a Treatment Option for Adults with Moderate to Severe Rheumatoid Arthritis

    Efficacy Results from a Phase 2 Study of Anti-IL-6 in Patients with Systemic Lupus Erythematosus

    Phase 1 Abstracts for Two Pfizer Biosimilars in Development; Both Assets Move into Phase 3 Comparability Trials

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that it will present data for several of its marketed and investigational medicines for inflammatory and immunological conditions at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2014 Annual Meeting (November 14-19, Boston, Massachusetts). Twenty-one abstracts for XELJANZ® (tofacitinib citrate) will be presented, including the six-year safety and efficacy analysesmore...
  • 11/6/14 8:00 am EST

    New educational program launches in honor of American Diabetes Month®

    NEW YORK--(BUSINESS WIRE)--Award-winning comedian and actor, Cedric “The Entertainer,” is getting serious as part of a new program – Step On Up™ – which aims to educate people, including the more than 29 million Americans living with diabetes about painful diabetic peripheral neuropathy, or diabetic nerve pain, a common complication of the disease. The program, which was developed as a collaboration between the American Diabetes Association and Pfizer Inc. (NYSE:PFE),more...
  • 11/5/14 11:00 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Group President, Vaccines, Oncology and Consumer Healthcare Business, at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014 at 8:00 a.m. Mountain Standard Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Credit Suisse 2014 Healthcare Conference” link in themore...
  • 10/29/14 2:44 pm EDT

    TRUMENBA is the First and Only Approved Vaccine in the U.S. for the Prevention of Meningococcal Meningitis B

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of TRUMENBA® (meningococcal group B vaccine) for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age. Approval of TRUMENBA is based on demonstration of immune response, as measured by serum bactericidal activity against four serogroup B strainsmore...
  • 10/29/14 8:30 am EDT

    Study Also Reinforces Existing Body of Clinical Evidence in Support of the Efficacy, Safety and Tolerability Profiles of PRISTIQ

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the publication of a clinical study in the Journal of Clinical Psychiatry showing comparable sexual function in adult patients diagnosed with major depressive disorder (MDD) treated daily with PRISTIQ Extended Release Tablets 50mg and 100mg doses versus placebo. Sexual dysfunction is often an issue for patients treated with antidepressants, and Pfizer conducted the study pursuant to a postmarketingmore...
  • 10/28/14 7:00 am EDT
    • Third-Quarter 2014 Reported Revenues(1) of $12.4 Billion
    • Third-Quarter 2014 Adjusted Diluted EPS(2) of $0.57, Reported Diluted EPS(1) of $0.42
    • Repurchased $4.2 Billion of Common Stock to Date in 2014
    • Updated Ranges for Certain 2014 Financial Guidance Components
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) reported financial results for third-quarter 2014. At the beginning of fiscal year 2014, the company began managing its commercial operations through a new global commercial structure consisting of three operating segments: the Global Innovative Pharmaceutical segment (GIP)(3); the Global Vaccines, Oncology and Consumer Healthcare segment (VOC)(3); and the Global Established Pharmaceutical segment (GEP)(3).more...
  • 10/27/14 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) has notified Pain Therapeutics, Inc. (NASDAQ: PTIE) that it has decided to discontinue its agreement to develop and commercialize REMOXY™ (oxycodone) Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics, Inc. Pfizer has concluded an internal review of the top-more...